MoneyBall Medicine: Niven Narain and how AI and Machine Learning are changing drug discovery



To listen to the podcast via iTunes click here

Harry interviews Niven Narain, the co-founder, president and CEO of BERG, a Boston-based biopharma company driving the next generation of drugs and diagnostics by combining patient-driven biology and AI to unravel actionable disease insight. Narain has overseen development of BERG’s clinical stage assets and pipeline and forged strategic partnerships with industry academic and US and UK governments. He says BERG’s philosophy is to combine a systems biology architecture with patients’ demographic data and clinical outcome data, and then apply Bayesian artificial intelligence algorithms to drive better understanding of diseases.

Want to hear more? Niven and Harry will be speaking at the AI Applications in Biopharma Summit in Boston in October. Click here to download the agenda.

At MoneyBall Medicine, host Harry Glorikian talks with leaders in the healthcare and life sciences industry about the ongoing data-driven transformation of their industry. Click here for more.